Newsletter Login



Forget your login?

30 Day Trial!

Activate Trial

Welcome to Dow Theory Forecasts

Dow Theory Forecasts is written with the busy reader in mind. Weekly stock recommendations and analysis is geared towards the individual investor looking for actionable stock market advice in a "just-the-facts" approach. Twice weekly hotlines with market news, stock upgrades and downgrades keep subscribers informed between issues.

View back issues in the Dow Theory Archive.

Subscription Scam Alert...please click here to read.

From the Current Newsletter:

September 29, 2014 issue

A premium for value

Following up a 30% price gain in 2013, the S&P 1500 Index has cruised to one all-time high after another on its way to a 7% rise this year.

Partly as a result, just 22% of S&P 1500 stocks trade below their five-year median price/earnings ratio, compared to an average of 40% since December 1994. Stocks available...

Read the rest of this article for more specific investing advice and stock investment information when you sign up for a FREE 30-day trial to Dow Theory Forecasts.

More Investment Newsletters and Services

Drip Investor

DRIP Investor — how you can buy dividend-paying stocks without a broker.

Visit us at DRIP Investor, your source for dividend reinvestment plans.

Lazy Investor

The Lazy Investor — free weekly e-letter that delivers market updates and stock market information via email.

Visit us at The Lazy Investor, our free investment newsletter.

Horizon Investment

Horizon — registered investment advisor seeks to provide investors at all stages the ability to build, preserve and enjoy wealth.

Visit us at Horizon Investment Services to get started in an investment program that's right for you.


Upside — discovers today's small and midcap stocks poised to be tomorrow's Blue Chip leaders.

Visit us at Upside, your guide to the best buys in small and midcap stocks.

Current Hotline

Friday, September 26, 2014

The sky has not fallen. Yes, the S&P 500 Index fell 1.6% yesterday and has dipped 2.3%

Read More from the Hotline

Stock Spotlight

Hepatitis cure drives growth at Gilead

Wednesday, September 24, 2014

None of our recommended picks enjoys stronger recent growth trends than Gilead Sciences ($105; GILD), which earns a maximum Momentum score of 100 in Quadrix. Its sales...

Read More from Stock Spotlight

Individual Stock Reports

ISRs make stock research easy!

Perhaps the most valuable two page reports available anywhere.

All the data you would normally have to plow through years of 10-K filings, earnings reports, and reams of market data to assemble — yours all in one concise report.

ISRs contain our proprietary Quadrix scores — find out how we rate all the stocks in the S&P 500.

Visit us at